Abbott Meets Q4 Earnings Estimates

Abbott (ABT - Free Report) came out with quarterly earnings of $0.81 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.74 per share a year ago. These figures are adjusted for non-recurring items.

A quarter ago, it was expected that this maker of infant formula, medical devices and drugs would post earnings of $0.74 per share when it actually produced earnings of $0.75, delivering a surprise of 1.35%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

Abbott, which belongs to the Zacks Medical - Products industry, posted revenues of $7.77 billion for the quarter ended December 2018, missing the Zacks Consensus Estimate by 0.29%. This compares to year-ago revenues of $7.59 billion. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Abbott shares have lost about 1.2% since the beginning of the year versus the S&P 500's gain of 5%.

What's Next for Abbott?

While Abbott has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

1 2
View single page >> |

Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this ...

more
How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.